Provenance / Rights / Review status
Follow the source. Preserve the uncertainty.
Original publication dates are retained. The review date records access, not when a discovery was made.
Researcher identity and attribution
Michael Levin’s Tufts faculty profile is an institutional identity source. Direct opening returned 403; search retrieval supplied the institutional profile text. The profile is undated; accessed 2026-10-22. Research authors are credited per paper, including Gizem Gumuskaya. A citation establishes no Karam relationship, endorsement or transfer of rights.
Prior art belongs in the workflow.
Published patent application · 2022-06-02WO2022115790A1
Engineered multicellular organisms
Published claims address self-motile apical-out ciliated multicellular aggregates and associated uses. Relevant prior art for Anthrobot-related development.
Inventors as listed: Michael Levin, Gizem Gumuskaya. Listed assignee: Tufts University. Priority as listed: 2020-11-30.
Google Patents publication text and claims accessible; official registers, national families and assignment chain not independently verified.
Next review: Map a concrete proposed implementation against relevant claims and disclosures, with qualified patent counsel.
Published patent application · 2026-02-12WO2026035859A1
Use of engineered multicellular organisms for screening antiaging and pro-regenerative compositions
Directly concerns antiaging/pro-regenerative screening with multicellular constructs. Published claims include longevity comparisons and methylation-clock analysis. The broad screening idea cannot be presented as new Karam IP.
Inventors as listed: Michael Levin. Listed assignee: Tufts University. Priority as listed: 2024-08-06.
Google Patents publication text and claims accessible; official registers, national families and assignment chain not independently verified.
Next review: Record dates, disclosures and concrete implementation differences; obtain claim-by-claim legal review before commercialization.
Tufts Biotech Opportunities supplies institutional commercialization context. Undated page, accessed 2026-10-22. It is not a license offer or evidence of a Karam deal.
Patentability
Unresolved: novelty and inventive distinction require a defined implementation and broader prior-art review.
Ownership
Unresolved: inventor and assignee labels do not establish Karam ownership or a verified assignment chain.
Licensing
Unresolved: no license, permission or partnership has been established.
Freedom to operate
Unresolved: jurisdiction-specific live claims and the proposed activity require separate review.
No permission is inferred from a database status label. No one has been contacted. Record a concrete implementation, contributors, provenance and planned activity before seeking separate qualified review.
Access blockers remain visible.
- 2025 clock algorithm and version
- 2025 preprocessing pipeline
- 2025 biological/technical replicate hierarchy
- 2023 exact donor count and experiment mapping
- Keratinocyte donor count and culture-to-donor mapping
- BETSE software and supplement were not independently run or audited.
- Xenopus endpoint-level hierarchy, supplement and raw data were not independently audited.
- Official patent registers, national-family claims and assignment chains remain unverified.
These limitations restrict conclusions. The public records and tools preserve unknown fields; they do not fill them with plausible guesses.